Literature DB >> 20459646

Global Assessment of Functioning (GAF): properties and frontier of current knowledge.

I H Monrad Aas1.   

Abstract

BACKGROUND: Global Assessment of Functioning (GAF) is well known internationally and widely used for scoring the severity of illness in psychiatry. Problems with GAF show a need for its further development (for example validity and reliability problems). The aim of the present study was to identify gaps in current knowledge about properties of GAF that are of interest for further development. Properties of GAF are defined as characteristic traits or attributes that serve to define GAF (or may have a role to define a future updated GAF).
METHODS: A thorough literature search was conducted.
RESULTS: A number of gaps in knowledge about the properties of GAF were identified: for example, the current GAF has a continuous scale, but is a continuous or categorical scale better? Scoring is not performed by setting a mark directly on a visual scale, but could this improve scoring? Would new anchor points, including key words and examples, improve GAF (anchor points for symptoms, functioning, positive mental health, prognosis, improvement of generic properties, exclusion criteria for scoring in 10-point intervals, and anchor points at the endpoints of the scale)? Is a change in the number of anchor points and their distribution over the total scale important? Could better instructions for scoring within 10-point intervals improve scoring? Internationally, both single and dual scales for GAF are used, but what is the advantage of having separate symptom and functioning scales? Symptom (GAF-S) and functioning (GAF-F) scales should score different dimensions and still be correlated, but what is the best combination of definitions for GAF-S and GAF-F? For GAF with more than two scales there is limited empirical testing, but what is gained or lost by using more than two scales?
CONCLUSIONS: In the history of GAF, its basic properties have undergone limited changes. Problems with GAF may, in part, be due to lack of a research programme testing the effects of different changes in basic properties. Given the widespread use, research-based development of GAF has not been especially strong. Further research could improve GAF.

Entities:  

Year:  2010        PMID: 20459646      PMCID: PMC2880316          DOI: 10.1186/1744-859X-9-20

Source DB:  PubMed          Journal:  Ann Gen Psychiatry        ISSN: 1744-859X            Impact factor:   3.455


  68 in total

Review 1.  Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients.

Authors:  E McColl; A Jacoby; L Thomas; J Soutter; C Bamford; N Steen; R Thomas; E Harvey; A Garratt; J Bond
Journal:  Health Technol Assess       Date:  2001       Impact factor: 4.014

2.  Optimal search strategies for retrieving systematic reviews from Medline: analytical survey.

Authors:  Victor M Montori; Nancy L Wilczynski; Douglas Morgan; R Brian Haynes
Journal:  BMJ       Date:  2004-12-24

3.  The MIRECC version of the Global Assessment of Functioning scale: reliability and validity.

Authors:  Noosha Niv; Amy N Cohen; Greer Sullivan; Alexander S Young
Journal:  Psychiatr Serv       Date:  2007-04       Impact factor: 3.084

4.  What is lost when searching only one literature database for articles relevant to injury prevention and safety promotion?

Authors:  D W Lawrence
Journal:  Inj Prev       Date:  2008-12       Impact factor: 2.399

5.  Scaling.

Authors:  F W Young
Journal:  Annu Rev Psychol       Date:  1984       Impact factor: 24.137

6.  Further measures of the psychometric properties of the Children's Global Assessment Scale.

Authors:  H R Bird; G Canino; M Rubio-Stipec; J C Ribera
Journal:  Arch Gen Psychiatry       Date:  1987-09

7.  Measurement of values for states of health with linear analog scales.

Authors:  H J Sutherland; V Dunn; N F Boyd
Journal:  Med Decis Making       Date:  1983       Impact factor: 2.583

8.  The Danish National Schizophrenia Project: prospective, comparative longitudinal treatment study of first-episode psychosis.

Authors:  Bent Rosenbaum; Kristian Valbak; Susanne Harder; Per Knudsen; Anne Køster; Matilde Lajer; Anne Lindhardt; Gerda Winther; Lone Petersen; Per Jørgensen; Merete Nordentoft; Anne Helms Andreasen
Journal:  Br J Psychiatry       Date:  2005-05       Impact factor: 9.319

9.  The longitudinal use of the Global Assessment Scale in multiple-rater situations.

Authors:  R J Dworkin; L C Friedman; R L Telschow; K D Grant; H S Moffic; V J Sloan
Journal:  Community Ment Health J       Date:  1990-08

10.  Scientific and clinical problems in indexes of functional disability.

Authors:  A R Feinstein; B R Josephy; C K Wells
Journal:  Ann Intern Med       Date:  1986-09       Impact factor: 25.391

View more
  60 in total

1.  Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis.

Authors:  Ángel Del Rey-Mejías; David Fraguas; Covadonga M Díaz-Caneja; Laura Pina-Camacho; Josefina Castro-Fornieles; Inmaculada Baeza; Ana Espliego; Jessica Merchán-Naranjo; Ana González-Pinto; Elena de la Serna; Beatriz Payá; Montserrat Graell; Celso Arango; Mara Parellada
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-03-01       Impact factor: 4.785

2.  Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment.

Authors:  Elsa Gilbert; Chantal Mérette; Valérie Jomphe; Claudia Emond; Nancie Rouleau; Roch-Hugo Bouchard; Marc-André Roy; Thomas Paccalet; Michel Maziade
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-31       Impact factor: 5.270

3.  Two-year follow-up of a Chinese sample at clinical high risk for psychosis: timeline of symptoms, help-seeking and conversion.

Authors:  T H Zhang; H J Li; K A Woodberry; L H Xu; Y Y Tang; Q Guo; H R Cui; X H Liu; A Chow; C B Li; K D Jiang; Z P Xiao; L J Seidman; J J Wang
Journal:  Epidemiol Psychiatr Sci       Date:  2016-04-08       Impact factor: 6.892

4.  Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla).

Authors:  Ulrike Stentzel; Neeltje van den Berg; Lara N Schulze; Thea Schwaneberg; Franziska Radicke; Jens M Langosch; Harald J Freyberger; Wolfgang Hoffmann; Hans-Jörgen Grabe
Journal:  BMC Psychiatry       Date:  2018-05-29       Impact factor: 3.630

5.  Deficits in reinforcement learning but no link to apathy in patients with schizophrenia.

Authors:  Matthias N Hartmann-Riemer; Steffen Aschenbrenner; Magdalena Bossert; Celina Westermann; Erich Seifritz; Philippe N Tobler; Matthias Weisbrod; Stefan Kaiser
Journal:  Sci Rep       Date:  2017-01-10       Impact factor: 4.379

6.  Peer support for people with schizophrenia or other serious mental illness.

Authors:  Wai Tong Chien; Andrew V Clifton; Sai Zhao; Steve Lui
Journal:  Cochrane Database Syst Rev       Date:  2019-04-04

7.  Quality of life across domains among individuals with treatment-resistant depression.

Authors:  Heidemarie Lex; Yarden Ginsburg; Adam F Sitzmann; Clara Grayhack; Daniel F Maixner; Brian J Mickey
Journal:  J Affect Disord       Date:  2018-09-19       Impact factor: 4.839

8.  Systematic review of global functioning and quality of life in people with psychotic disorders.

Authors:  A G Nevarez-Flores; K Sanderson; M Breslin; V J Carr; V A Morgan; A L Neil
Journal:  Epidemiol Psychiatr Sci       Date:  2018-10-01       Impact factor: 6.892

9.  Telemedical care and quality of life in patients with schizophrenia and bipolar disorder: results of a randomized controlled trial.

Authors:  Ulrike Stentzel; Neeltje van den Berg; Kilson Moon; Lara N Schulze; Josephine Schulte; Jens M Langosch; Wolfgang Hoffmann; Hans J Grabe
Journal:  BMC Psychiatry       Date:  2021-06-29       Impact factor: 3.630

10.  Outcomes of anticoagulation therapy in patients with mental health conditions.

Authors:  Helen T Paradise; Dan R Berlowitz; Al Ozonoff; Donald R Miller; Elaine M Hylek; Arlene S Ash; Guneet K Jasuja; Shibei Zhao; Joel I Reisman; Adam J Rose
Journal:  J Gen Intern Med       Date:  2014-02-19       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.